Zhimeng Biopharma's investigational drug CB03-154 for amyotrophic lateral sclerosis has achieved the first patient first dose milestone in the phase 2/3 pivotal clinical trial.
SHANGHAI, Oct. 31, 2025 /PRNewswire/ -- Shanghai Zhimeng Biopharma Inc. ( "Zhimeng") announced that its self-developed new-generation potassium channel opener CB03-154 for the treatment of amyotrophic lateral sclerosis (ALS) has officially initiated...
MetaOptics Announces Strategic Expansion into the USA with Nevada Incorporation and Advanced 127μm Co-Packaged Optics Breakthrough
SINGAPORE, Oct. 29, 2025 /PRNewswire/ -- MetaOptics Ltd (Catalist: 9MT) ("MetaOptics"), a leading-edge semiconductor optics company pioneering metalens technology, is pleased to announce the establishment of its United States entity, MetaOptics Inc....
BioDlink Completes First International Shipment of Bevacizumab to Colombia
Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top three cancers ranked by death in Colombia[1]. This inaugural shipment—dispatched around two months after Colombia's marketing approval—demonstrates the...
Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO
CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, Results from a Phase 3 study of...
ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key...
Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC
CHENGDU, China, Oct. 17, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) trastuzumab botidotin...
Turfan, Xinjiang: Electricity Ensures Steady Development of a 3-Billion-Yuan Energy Hub
TURFAN, China, June 24, 2025 /PRNewswire/ -- On June 24, the temporary construction phase of the No. 1 Open-Pit Mine in the Kumtag Mining Area, located in Shanshan County, Turfan City, Xinjiang, officially commenced. This marks the entry of this key...
Forum held to promote cooperation between China, Central Asia news agencies
ASTANA, Kazakhstan, June 24, 2025 /PRNewswire/ -- This is a report from Xinhuanet: President of Xinhua News Agency Fu Hua attends the China-Central Asia News Agency Forum in Astana, Kazakhstan, June 22, 2025. The China-Central Asia News Agency Forum...
IASO Bio presents promising efficacy of Equecabtagene Autoleucel in patients with Multiple Sclerosis in IIT study at the 11th Congress of the European Academy of Neurology (EAN)
SHANGHAI and NANJING, China and SAN FRANCISCO, June 23, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and...
SNEC 2025｜Hithium Defines a New Benchmark for Energy Storage Safety with the World's First All Open-Door Large-Scale Fire Test
SHANGHAI, June 13, 2025 /PRNewswire/ -- On June 11, 2025, at the 18th SNEC, Hithium, a leading global energy storage technology company, held a product safety technology sharing event themed Leading the Future, Forged for Safety and unveiled the...